Quantum-SI Incorporated

Quantum-SI Incorporated (NASDAQ: QSI) is a life sciences company. The Company has designed and developed a hardware, consumable and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.

Key Business and Financial Updates:

• Quantum-Si Incorporated: Recent Developments and Strategic Positioning: Quantum-Si Incorporated, a life-sciences and proteomics company specialising in next-generation protein sequencing (NGPS™), has taken a number of significant steps recently that underscore its technology-driven growth ambition. Notably, in September 2025, the company launched its V4 Sequencing Kit, which provides an 85% increase in sequenceable peptides compared to the prior version, expands amino-acid coverage (including glycine, alanine, serine, and proline-rich domains), and enables higher-plex barcoding (24-plex) for complex sample mixtures. In parallel, Quantum-Si priced a USD 50 million registered direct offering of its common stock in July 2025, broadening its cash runway. These developments reflect both technological advancement and capital-strengthening for the company’s product commercialisation path.
• Commercialisation & Technology Opportunity: At its core, Quantum-Si’s platform offers single-molecule protein sequencing—a capability that surpasses the resolution of traditional mass spectrometry and immuno-assay workflows by detecting amino-acid sequence variants and post-translational modifications with high precision. The company’s instrument portfolio, including the Platinum® and Platinum® Pro systems, along with consumables (library prep kits, barcoding kits, sequencing kits) and software (Platinum Analysis Software), creates an integrated hardware-consumable-software business model. The new V4 kit further extends the addressable applications—from antibody sequencing to proteoform detection—and potentially strengthens Quantum-Si’s competitive positioning in the emerging proteomics market.
• Financial & Funding Status: Despite promising technology, Quantum-Si remains in the early stages of revenue generation, with modest top-line figures and ongoing net losses. However, the recent USD 50 million capital raise enhances liquidity and extends the company’s runway into future commercial phases. Management continues to focus on translating its advanced technology into sustainable revenue growth and profitability. Investors should monitor cash-burn levels, instrument placement pace, consumable adoption rates, and gross margin improvements as indicators of operational progress.
• Near-Term Outlook and Key Catalysts: In the near term, key catalysts for Quantum-Si include the commercial rollout of the V4 kit and increased instrument placements across research institutions and pharmaceutical partnerships. The company’s expanding software and barcoding ecosystem aims to drive recurring consumable and analytics revenue. Active participation in global industry conferences is expected to strengthen brand visibility and accelerate strategic partnerships. With careful capital deployment and disciplined execution, Quantum-Si is well-positioned to leverage its innovation pipeline for commercial growth.
• Decision-Making Considerations for Clients: For clients considering exposure to Quantum-Si, several factors warrant attention. The company’s NGPS platform offers clear technological differentiation but has yet to fully demonstrate commercial scalability. Revenue ramp-up timelines may extend due to adoption cycles and market competition, while ongoing cash burn introduces dilution risks. Nevertheless, the expanding proteomics market presents significant long-term opportunities. Quantum-Si’s recent product innovation, strengthened liquidity, and strategic execution suggest improving fundamentals. The stock may appeal to investors with a high-risk tolerance and a long-term outlook, seeking exposure to cutting-edge advancements in molecular and protein sequencing.

Technical Observation (on the daily chart):

• Price Trend and Moving Averages: Quantum-Si Incorporated (NASDAQ: QSI) is trading at USD 2.29, reflecting a steady uptrend from its 52-week low of USD 0.61, signaling a gradual recovery in investor sentiment. The stock is trading above both its 50-day (USD 1.56) and 200-day (USD 1.60) moving averages, forming a bullish alignment that indicates strengthening medium-term momentum and improved price structure stability.
• Momentum Indicators and Market Sentiment: The Relative Strength Index (RSI) stands at 60.40, suggesting moderately bullish momentum with room for further upside before entering overbought territory. This indicates growing accumulation and improving sentiment as buyers gain confidence following a period of consolidation, likely supported by recent fundamental advancements and positive investor outlook.
• Technical Outlook and Key Levels: QSI faces near-term resistance around USD 2.50–2.70, while key support is positioned near USD 1.90–2.00, levels critical for sustaining its bullish trajectory. A breakout above resistance could open the path toward the USD 3.00 level in the short term, while sustained trading above the 200-day moving average would reinforce the stock’s ongoing recovery trend.

As per the above-mentioned price action, important support near USD 1.80-USD 2.00, momentum in the stock over the last month, and technical indicators analysis, a ‘WATCH’ rating has been given for Quantum-SI Incorporated (NASDAQ: QSI) at the current price of USD 2.29, as of October 27, 2025, at 07:40 am PDT. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective, and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is October 27, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.